On August 21, 2025, Iovance Biotherapeutics, Inc. approved the granting of inducement stock options for 182,370 shares of the company's common stock to 20 new non-executive employees. Iovance is a biotechnology firm specializing in developing polyclonal tumor infiltrating lymphocyte therapies for cancer patients. The stock options were given on the Date of Grant to enhance the company's workforce.